A recent study of men with stage IV prostate cancer revealed that liver-only metastasis is associated with worse cancer-specific and overall survival than bone-only and lung-only metastasis
In a single-institution study, men with oligometastatic prostate cancer who received stereotactic ablative radiation to metastatic lesions had a 52% rate of biochemical progression-free survival at 1 year, a study found.
In a study, men who had pre-existing cardiovascular disease prior to taking abiraterone or enzalutamide for advanced prostate cancer had a 16% to 56% increased 6-month risk.
In a large study, men who underwent radical prostatectomy at centers that had the largest annual prostate cancer caseload lived a median 13.2 months longer than those who had the surgery at centers with the lowest caseload.
Large observational study reveals a 40% cumulative incidence rate of first skeletal-related events following development of castration-resistant prostate cancer.
Hypofractionated radiotherapy (HRT) offers quality-of-life outcomes similar to conventional radiation therapy for men with low-risk prostate cancer, according to recently published results of a phase 3 randomized study. HRT offers a less expensive and more convenient treatment option for some patients, and in light of the new findings about quality of life, should be considered…
In a study, natural killer cell activity (NKA) below 200 pg/mL predicted a nearly 5-fold greater risk of having a positive prostate biopsy compared with higher NKA values.
Ultra-hypofractionated and conventionally fractionated radiotherapy for intermediate- or high-risk prostate cancer are associated with similar 5-year failure-free survival rates, a randomized phase 3 trial found.
Adjuvant radiotherapy following radical prostatectomy (RP) for PCa with positive margins or extracapsular extension prolongs biochemical recurrence-free survival compared with RP alone, a study found.
In the phase 3 ARAMIS trial, darolutamide, a nonsteroidal androgen receptor inhibitor, significantly delayed development of metastasis in men with nonmetastatic castration-resistant prostate cancer.